Literature DB >> 1697356

Some old and some new ideas on kinin metabolism.

E G Erdös1.   

Abstract

Enzymes that hydrolyze kinins are known under the collective term of "kininases." This short review surveys kininase I- and II-type enzymes. For the sake of simplicity, we call carboxypeptidases that remove the C-terminal arginine of kinins kininase I-type enzymes. Plasma carboxypeptidase N and the cell membrane-bound carboxypeptidase M belong here. Kininase II enzymes release the C-terminal dipeptide Phe-Arg; angiotensin I-converting enzyme and neutral endopeptidase 24.11 (enkephalinase) are prominent members of this subgroup of proteins. The primary sequence of five proteins of the four human kininases (including the catalytic and regulatory subunits of carboxypeptidase N) were deduced from the nucleotide sequence of their cDNAs. The structure and properties of these enzymes are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697356

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.

Authors:  Keith L Black; Dali Yin; John M Ong; Jinwei Hu; Bindu M Konda; Xiao Wang; MinHee K Ko; Jennifer-Ann Bayan; Manuel R Sacapano; Andreas Espinoza; Dwain K Irvin; Yan Shu
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

2.  Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells.

Authors:  R Busse; D Lamontagne
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

3.  Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors.

Authors:  T Hedner; O Samuelsson; H Lunde; L Lindholm; L Andrén; B E Wiholm
Journal:  BMJ       Date:  1992-04-11

Review 4.  Pharmacological blood-brain barrier modification for selective drug delivery.

Authors:  T F Cloughesy; K L Black
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

Review 5.  The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.

Authors:  D F Emerich; R L Dean; C Osborn; R T Bartus
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats.

Authors:  Danielle R Santos; João B Calixto; Glória E P Souza
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 7.  Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2007-08-15       Impact factor: 4.932

8.  Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.

Authors:  M Hecker; I Pörsti; A T Bara; R Busse
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

9.  Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

Authors:  R M Fryer; J Segreti; P N Banfor; D L Widomski; B J Backes; C W Lin; S J Ballaron; B F Cox; J M Trevillyan; G A Reinhart; T W von Geldern
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

Review 10.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.